Metabolism of the anti-tuberculosis drug ethionamide by mouse and human FMO1, FMO2 and FMO3 and mouse and human lung microsomes

Toxicology and Applied Pharmacology

Volumn 233, Issue 3, 2008, Pages 420-427

  Henderson, Marilyn C ^a   Siddens, Lisbeth K ^a   Morré, Jeffrey T ^a   Krueger, Sharon K ^b   Williams, David E ^a,b  

^a OREGON STATE UNIVERSITY   (United States)

^b OREGON STATE UNIVERSITY   (United States)

Author keywords

Ethionamide; Flavin containing monooxygenase; Tuberculosis

Indexed keywords

2 ETHYL 4 AMIDOPYRIDINE; DIMETHYLANILINE MONOOXYGENASE; DIMETHYLANILINE MONOOXYGENASE 1; DIMETHYLANILINE MONOOXYGENASE 2; DIMETHYLANILINE MONOOXYGENASE 3; DRUG METABOLITE; ETHIONAMIDE; GLUTATHIONE; PROADIFEN; SULFINIC ACID DERIVATIVE; SULFOXIDE; THIOUREA; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL STRAIN; CHEMICAL REACTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVATION; DRUG EFFICACY; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME SUBSTRATE; GENETIC POLYMORPHISM; HUMAN; LIVER MICROSOME; LUNG MICROSOME; MICROSOME; MOUSE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OXYGENATION; PROTEIN EXPRESSION; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ETHIONAMIDE; GLUTATHIONE; HUMANS; LUNG; MASS SPECTROMETRY; MICE; MICROSOMES; MICROSOMES, LIVER; OXYGENASES;

MAMMALIA; MYCOBACTERIUM TUBERCULOSIS;

EID: 56249123296     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2008.09.017     Document Type: Article

References (60)

1. API Consensus Expert Committee. API TB consensus guidelines 2006: management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations. J. Assoc. Phys. India 54 (2006) 219-234
2. Baulard A.R., Betts J.C., Engohang-Ndong J., Quan S., McAdam R.A., Brennan P.J., Locht C., and Besra G.S. Activation of the pro-drug ethionamide is regulated in mycobacteria. J. Biol. Chem. 275 (2000) 28326-28331
3. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 53 (1976) 332-336
4. Cashman J.R. The role of flavin-containing monooxygenases in drug metabolism and development. Curr. Opin. Drug Discov. Devel. 6 (2003) 486-493
5. Cashman J.R. Structure and catalytic properties of the mammalian flavin-containing monooxygenase. Chem. Res. Toxicol. 8 (1995) 165-181
6. Cashman J.R., Park S.B., Berkman C.E., and Cashman L.E. Role of hepatic flavin-containing monooxygenase in drug and chemical metabolism in adult humans. Chem.-Biol. Interact. 96 (1995) 33-46
7. Chimote G., and Banerjee R. Evaluation of antitubercular drug-loaded surfactants as inhalable drug-delivery systems for pulmonary tuberculosis. J. Biomed. Mater. Res. A. (2008) April 22 [Electronic publication ahead of print] PMID 18431766
8. Conte Jr. J.E., Golden J.A., McQuitty M., Kipps J., Lin E.T., and Zurlinden E. Effects of AIDS and gender on steady-state plasma and intrapulmonary ethionamide concentrations. Antimicrob. Agents Chemother. 44 (2000) 1337-1341
9. Cynamon M.H., and Sklaney M. Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis. Antimicrob. Agents Chemother. 47 (2003) 2442-2444
10. Cynamon M.H., Klemens S.P., Sharpe C.A., and Chase S. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob. Agents Chemother. 43 (1999) 1189-1191
11. DeBarber A.E., Mdluli K., Bosman M., Bekker L.G., and Barry III C.E. Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 9677-9682
12. Dixon B.M., Heath S.-H.D., Kim R., Suh J.H., and Hagen T.M. Assessment of endoplasmic reticulum glutathione redox status is confounded by extensive ex vivo oxidation. Antioxid. Redox Signal. 10 (2008) 963-972
13. Dolphin C.T., Beckett D.J., Janmohamed A., Cullingford T.E., Smith R.L., Shephard E.A., and Phillips I.R. The flavin-containing monooxygenase 2 gene (FMO2) of humans, but not of other primates, encodes a truncated, nonfunctional protein. J. Biol. Chem. 273 (1998) 30599-30607
14. Donald P.R., Schoeman J.F., and O'Kennedy A. Hepatic toxicity during chemotherapy for severe tuberculosis meningitis. Am. J. Dis. Child. 141 (1987) 741-743
15. Dover L.G., Alahari A., Gratraud P., Gomes J.M., Bhowruth V., Reynolds R.C., Besra G.S., and Kremer L. EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets. Antimicrob. Agents Chemother. 51 (2007) 1055-1063
16. Fraaije M.W., Kamerbeek N.M., Heidekamp A.J., Fortin R., and Janssen D.B. The prodrug activator EtaA from Mycobacterium tuberculosis is a Baeyer-Villiger monooxygenase. J. Biol. Chem. 279 (2004) 3354-3360
17. Furnes B., Feng J., Sommer S.S., and Schlenk D. Identification of novel variants of the flavin-containing monooxygenase gene family in African Americans. Drug Metab. Disp. 31 (2003) 187-193
18. Hanoulle X., Wieruszeski J.M., Rousselot-Pailley P., Landrieu I., Locht C., Lippens G., and Baulard A.R. Selective intracellular accumulation of the major metabolite issued from the activation of the prodrug ethionamide in mycobacteria. J. Antimicrob. Chemother. 58 (2006) 768-772
19. Harries A.D., and Dye C. Tuberculosis. Ann. Trop. Med. Parasitol. 100 (2006) 415-431
20. Henderson M.C., Krueger S.K., Siddens L.K., Stevens J.F., and Williams D.E. S-Oxygenation of the thioether organophosphate insecticides phorate and disulfoton by human lung flavin-containing monooxygenase 2. Biochem. Pharmacol. 68 (2004) 959-967
21. Henderson M.C., Krueger S.K., Stevens J.F., and Williams D.E. Human flavin-containing monooxygenase form 2 S-oxygenation: sulfenic acid formation from thioureas and oxidation of glutathione. Chem. Res. Toxicol. 17 (2004) 633-640
22. Hernandez D., Janmohamed A., Chandan P., Phillips I.R., and Shephard E.A. Organization and evolution of the flavin-containing monooxygenase genes of human and mouse: identification of novel gene and pseudogene clusters. Pharmacogenetics 14 (2004) 117-130
23. Hines R.N. Developmental and tissue-specific expression of human flavin-containing monooxygenase 1 and 3. Expert Opin. Drug Metab. Toxicol. 2 (2006) 41-49
24. Hines R.N., Hopp K.A., Franco J., Sacian K., and Begun F.P. Alternative processing of the human FMO6 gene renders transcripts incapable of encoding a functional flavin-containing monooxygenase. Mol. Pharmacol. 62 (2002) 320-325
25. Hwang S.M., Kim D.D., Chung S.J., and Shim C.K. Delivery of ofloxacin to the lung and alveolar macrophages via hyaluronan microspheres for the treatment of tuberculosis. J. Control. Release 129 (2008) 100-106
26. Janmohamed A., Hernandez D., Phillips I.R., and Shephard E.A. Cell-, tissue-, sex- and developmental stage-specific expression of mouse flavin-containing monooxygenases (Fmos). Biochem. Pharmacol. 68 (2004) 73-83
27. Klemens S.P., DeStefano M.S., and Cynamon M.H. Therapy of multidrug-resistant tuberculosis: lessons from studies with mice. Antimicrob. Agents Chemother. 37 (1993) 2344-2347
28. Kochi A. Tuberculosis: distribution, risk factors, mortality. Immunobiol. 191 (1994) 325-336
29. Koukouritaki S.B., Simpson P., Yeung C.K., Rettie A.E., and Hines R.N. Human hepatic flavin-containing monooxygenase 1 (FMO1) and 3 (FMO3) developmental expression. Pediatr. Res. 51 (2002) 236-243
30. Krieter P.A., Ziegler D.M., Hill K.E., and Burk R.F. Increased biliary GSSG efflux from rat livers perfused with thiocarbamides substrates for the flavin-containing monooxygenase. Molec. Pharmacol. 26 (1984) 122-127
31. Krueger S.K., and Williams D.E. Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol. Therap. 106 (2005) 357-387
32. Krueger S.K., Martin S.R., Yueh M.-F., Pereira C.B., and Williams D.E. Identification of active flavin-containing monooxygenase isoform 2 in human lung and characterization of expressed protein. Drug Metab. Dispos. 30 (2002) 34-41
33. Krueger S.K., Siddens L.K., Henderson M.C., Andreasen E.A., Tanguay R.L., Pereira C.B., Cabacungan E.T., Hines R.N., Ardlie K.G., and Williams D.E. Haplotype and functional analysis of four flavin-containing monooxygenase isoform 2 (FMO2) polymorphisms in Hispanics. Pharmacogenet. Genomics 15 (2005) 245-256
34. Krueger S.K., Siddens L.K., Martin S.R., Yu A., Pereira C.B., Cabacungan E.T., Hines R.N., Ardlie K.G., Raucy J.L., and Williams D.E. Differences in FMO2*1 allelic frequency between Hispanics of Puerto Rican and Mexican descent. Drug Metab. Disp. 32 (2004) 1337-1340
35. Krueger S.K., Williams D.E., Yueh M.-F., Martin S.R., Hines R.N., Raucy J.L., Dolphin C.T., Shephard E.A., and Phillips I.R. Genetic polymorphisms of flavin-containing monooxygenase (FMO). Drug Metabol. Rev. 34 (2002) 523-532
36. Krueger S.K., Yueh M.-F., Martin S.R., Pereira C.B., and Williams D.E. Characterization of expressed full-length and truncated FMO2 from rhesus monkey. Drug Metab. Disp. 29 (2001) 693-700
37. Kruijshaar M.E., Watson J.M., Drobniewski F., Anderson C., Brown T.J., Magee J.G., Smith E.G., Story A., and Abubakar I. Increasing antituberculosis drug resistance in the United Kingdom: analysis of National Surveillance Data. Br. Med. J. 336 (2008) 1231-1234
38. Lu P.L., Peng C.F., Hwang J.J., and Chen Y.H. Activity of twelve second-line antimicrobial agents against Mycobacterium tuberculosis in Taiwan. J. Chemother. 20 (2008) 202-207
39. McIlleron H., Wash P., Burger A., Norman J., Folb P.I., and Smith P. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of Tuberculosis patients. Antimicrob. Agents Chemother. 50 (2006) 1170-1177
40. Neal R.A., and Halpert J. Toxicology of thiono-sulfur compounds. Ann. Rev. Pharmacol. Toxicol. 22 (1982) 321-339
41. Onderwater R.C.A., Commandeur J.N.M., and Vermeulen N.P.E. Comparative cytotoxicity of N′-substituted N′-(4-imidazole-ethyl)thiourea in precision-cut rat liver slices. Toxicol. 197 (2004) 81-91
42. Phetsuksiri B., Jackson M., Scherman H., McNeil M., Besra G.S., Baulard A.R., Slayden R.A., DeBarber A.E., Barry III C.E., Baird M.S., Crick D.C., and Brennan P.J. Unique mechanism of action of the thiourea drug isoxyl on Mycobacterium tuberculosis. J. Biol. Chem. 278 (2003) 53123-53130
43. Phillips I.R., and Shephard E.A. Flavin-containing monooxygenases: mutations, disease and drug response. Trends Pharmacol. Sci. 29 (2008) 294-301
44. Qian L., and Ortiz de Montellano P.R. Oxidative activation on thiacetazone by the Mycobacterium tuberculosis flavin monooxygenase EtaA and human FMO1 and FMO3. Chem. Res. Toxicol. 19 (2006) 443-449
45. Russ M.J., and Waring R.H. The effect of methimazole on thioamide bioactivation and toxicity. Toxicol. Lett. 58 (1991) 37-41
46. See A., Hervio P., and Bouvry M. The hepatotoxicity of ethionamide remains a topical subject. Apropos of a case of acute hepatitis. Ann. Gastroenterol. Hepatol. (Paris). 22 (1986) 129-130
47. Shehin-Johnson S., Williams D.E., Larsen-Su S., Stresser D.M., and Hines D.M. Tissue-specific expression of flavin-containing monooxygenase (FMO) forms 1 and 2 in the rabbit. J. Pharmacol. Exp. Therap. 272 (1995) 1293-1299
48. Shi R., Itagaki N., and Sugawara I. Overview of anti-tuberculosis (TB) drugs and their resistance mechanisms. Mini Rev. Med. Chem. 7 (2007) 1177-1185
49. Siddens L.K., Henderson M.C., VanDyke J.E., Williams D.E., and Krueger S.K. Characterization of mouse flavin-containing monooxygenase transcript levels in lung and liver, and activity of expressed isoforms. Biochem. Pharmacol. 75 (2008) 750-759
50. Smith P.B., and Crespi C. Thiourea toxicity in mouse C3H/10T1/2 cells expressing human flavin-containing monooxygenase 3. Biochem. Pharmacol. 63 (2002) 1941-1948
51. Umubyeyi A., Rigouts L., Shamputa I.C., Dediste A., Struelens M., and Portaels F. Low levels of second-line drug resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Rwanda. Int. J. Infect. Dis. 12 (2008) 152-156
52. Vannelli T.A., Dykman A., and Ortiz de Montellano P.R. The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase. J. Biol. Chem. 277 (2002) 12824-12829
53. Wada M. The adverse reactions of anti-tuberculosis drugs and its management. Nippon Rinsho. 56 (1998) 3091-3095
54. Wang F., Langley R., Gulten G., Dover L.G., Besra G.S., Jacobs Jr. W.R., and Sacchettini J.C. Mechanism of thioamide drug action against tuberculosis and leprosy. J. Exp. Med. 204 (2007) 73-78
55. Weyer K., and Kleeberg H.H. Primary and acquired drug resistance in adult black patients with tuberculosis in South Africa: results of a continuous national drug resistance surveillance programme involvement. Tuber. Lung Dis. 73 (1992) 106-112
56. Whetstine J.R., Yueh M.-F., Hopp K.A., McCarver D.G., Williams D.E., Park C.-S., Kang J.H., Cha Y.-N., Dolphin C.T., Shephard E.A., Phillips I.R., and Hines R.N. Ethnic differences in human flavin-containing monooxygenase 2 (FMO2) polymorphisms: detection of expressed protein in African Americans. Toxicol. Appl. Pharmacol. 168 (2000) 216-224
57. World Health Organization, 1993. http://www.who.int/mediacentre/factsheets/fs104/en/index.html.
58. Yeung C.K., Lang D.H., Thummel K.E., and Rettie A.E. Immunoquantitation of FMO1 in human liver, kidney, and intestine. Drug Metab. Disp. 28 (2000) 1107-1111
59. Ziegler D.M. Flavin-containing monooxygenases: catalytic mechanism and substrate specificities. Drug Metab. Rev. 19 (1988) 1-32
60. Ziegler D.M. An overview of the mechanism, substrate specificities and structure of FMOs. Drug Metab. Rev. 34 (2002) 503-511